Menu
Back to Journals » Neuropsychiatric Disease and Treatment » Volume 18
Evaluation of α-Synuclein and Apolipoprotein E as Potential Biomarkers in Cerebrospinal Fluid to Monitor Pharmacotherapeutic Efficacy in Dopamine Dictated Disease States of Parkinson’s Disease and Schizophrenia [Corrigendum]
Authors Gupta AK, Pokhriyal R, Das U , Khan MI, Ratna Kumar D, Gupta R, Chadda RK, Ramachandran R, Goyal V, Tripathi M, Hariprasad G
Received 20 June 2022
Accepted for publication 20 June 2022
Published 27 June 2022 Volume 2022:18 Pages 1271—1272
Gupta AK, Pokhriyal R, Das U, et al. Neuropsychiatr Dis Treat. 2019;15:2073–2085.
The authors wish to advise of typographical errors in Figures 1 and 2 and Table 3, the correct unit of apolipoprotein E concentration is μg/ml, and not pg/ml.
Page 2077, Figure 1A, y axis, the text “CSF apolipoprotein E (pg/ml)” should read “CSF apolipoprotein E (μg/ml)”.
Page 2077, Figure 2, x axis, the text “CSF apolipoprotein E (pg/ml)” should read “CSF apolipoprotein E (µg/ml)”.
Page 2079, Table 3, Cut-off values to differentiate neurological controls from the disease column, Apolipoprotein E and Apolipoprotein E or α-synuclein rows, the text “>3.4 pg (Parkinson’s disease)” should read “>3.4 µg (Parkinson’s disease)” and “
The authors apologize for these errors and any inconvenience.
© 2022 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.